Updated 00:43 GMT, 7 Nov 2026 SPX 7,376.86 +0.31% NDX 26,989.99 +1.35% VIX 25.64 -9.01% GOLD 4,079.50 -0.83% CL 90.34 -0.20% BTC 75,812.80 -0.17%
NAS100 26,990 +1.35% S&P 7,377 +0.31% GOLD $4,080 −0.83% BTC $75,813 −0.17% VIX 25.64 −9.01% prices · as of 00:43 UTC
Vol. II · No. 311Saturday, 7 November 2026
TTitan Protect
Case Studies · Earnings Echo

Why We’re Passing on AbbVie Despite the Beat.

Filed Friday 30 October 2026 · 23:29 UTC · Entry no. 133170 · scored against the close · never edited

Why We’re Passing on AbbVie Despite the Beat.
Earnings Review · 30 October 2026
The print
Revenue $16.99B. EPS $3.82 vs $3.77 expected.
What changed versus going in
Earnings came in at $3.82 a share against $3.77 expected, a beat of 1% (+$0.05 a share). Revenue of $16.99B compares with $17.30B expected, 1.8% below consensus.
Did the flow confirm the move?
Money has been flowing IN underneath a flat-to-lower price: quiet accumulation, the kind of positioning that tends to show up before a name moves, not after. (21-day Chaikin Money Flow +0.12, five-day price change -0.9%, as of 2026-10-27, desk flow model).
Give the business its due
The business itself is genuinely strong: revenue growing about 10%, net margins near 10%.
Levels that matter
At $286.39 the shares sit 2% below the 52-week high of $292.58 and 50% above the low of $190.75 (94% of the way up the range). The 50-day average is $266.12, below the price. The 200-day average is $232.89, below the price.
The valuation lens
The shares trade about 11% below our fair-value estimate: a modest cushion. Fair value lands near $322 against a $290.79 share price, a margin of safety of about 11%. The trailing multiple sits around 82 times earnings, which only makes sense if the growth holds.
The ethical lens, our differentiator
The two standards split: it clears the faith-based (AAOIFI) screen but not our broader anchor screen. We default to protection and do not call it compliant on a divergence.
The compliant alternative
If the theme is what draws you, Sanofi SA (SAN.PA) sits in the same industry (Drug Manufacturers – General) and clears our principled screen, the place to look instead of chasing a name that does not.
The verdict for a values-conscious investor
A beat-and-raise does not change the screen. This is a great company you can admire without owning, protection first. One quarter, strong or soft, does not decide whether a holding is suitable.

This is analysis, not financial advice. Always manage your risk.

How This Entry Scores

Every level named in a session brief is scored against the next scheduled close. Nothing is edited after filing: if a level breaks, the record shows it as filed, not as corrected. The desk's full scored history sits on the track record page.

Continue Reading View all Case Studies →
Membership

The ledger is public. The desk behind it is not.

Membership opens every room and every entry the day it is filed, with the same dated honesty the record is built on.

Join the desk

This is analysis, not financial advice. Always manage your risk.

Get our weekly market brief free.